A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety, Tolerability and Efficacy of Two Doses of Subcutaneous IPP-201101 Plus Standard of Care, Versus Placebo Plus Standard of Care in Subjects with Systemic Lupus Erythematosus (SLE)
100 项与 Immupharma (France) SA 相关的临床结果
0 项与 Immupharma (France) SA 相关的专利(医药)
100 项与 Immupharma (France) SA 相关的药物交易
100 项与 Immupharma (France) SA 相关的转化医学